Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jonathan Shue"'
Autor:
Shigeki Nanjo, Wei Wu, Niki Karachaliou, Collin M. Blakely, Junji Suzuki, Yu-Ting Chou, Siraj M. Ali, D. Lucas Kerr, Victor R. Olivas, Jonathan Shue, Julia Rotow, Manasi K. Mayekar, Franziska Haderk, Nilanjana Chatterjee, Anatoly Urisman, Jia Chi Yeo, Anders J. Skanderup, Aaron C. Tan, Wai Leong Tam, Oscar Arrieta, Kazuyoshi Hosomichi, Akihiro Nishiyama, Seiji Yano, Yuriy Kirichok, Daniel S.W. Tan, Rafael Rosell, Ross A Okimoto, Trever G. Bivona
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 13 (2022)
Molecularly targeted cancer therapy has improved outcomes for patients with cancer with targetable oncoproteins, such as mutant EGFR in lung cancer. Yet, the long-term survival of these patients remains limited, because treatment responses are typica
Externí odkaz:
https://doaj.org/article/2ab24c64ef0a4efabc727bb6d4218018
Autor:
Ross A. Okimoto, Jonathan Shue, Collin M. Blakely, Niki Karachaliou, Trever G. Bivona, Yuriy Kirichok, Julia K Rotow, Siraj M. Ali, Victor Olivas, Anatoly Urisman, Wei Wu, Junji Suzuki, Daniel Shao-Weng Tan, Rafael Rosell, Franziska Haderk, Shigeki Nanjo, Manasi K. Mayekar, D. Lucas Kerr, Nilanjana Chatterjee
Molecularly targeted cancer therapy has improved outcomes for cancer patients with targetable oncoproteins, such as mutant epidermal growth factor receptor (EGFR) in lung cancer. Yet, long-term patient survival remains limited because treatment respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d74422e112b9ffa7794c0d30837e7ea0
https://doi.org/10.1101/2020.10.26.356352
https://doi.org/10.1101/2020.10.26.356352
